

David J H Shih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7086308/publications.pdf>

Version: 2024-02-01

50
papers

9,152
citations

126907

33
h-index

254184

43
g-index

51
all docs

51
docs citations

51
times ranked

11965
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
3	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
4	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	28.9	743
5	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	16.8	627
6	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	27.8	521
7	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	27.8	520
8	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
9	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	27.8	376
10	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , 2012, 123, 615-626.	7.7	318
11	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
12	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
13	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
14	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
15	MRI Surrogates for Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2014, 35, 1263-1269.	2.4	257
16	Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors. <i>Cancer Cell</i> , 2009, 16, 533-546.	16.8	207
17	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	7.7	195
18	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177

#	ARTICLE	IF	CITATIONS
19	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169
20	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
21	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	21.4	112
22	The G protein α subunit $G\alpha$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	30.7	110
23	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
24	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , 2018, 172, 1050-1062.e14.	28.9	85
25	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192.	7.0	84
26	Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. <i>Nature Communications</i> , 2020, 11, 1806.	12.8	62
27	Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. <i>Cancer Research</i> , 2013, 73, 6310-6322.	0.9	52
28	Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. <i>Oncogene</i> , 2017, 36, 5231-5242.	5.9	43
29	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1190-1194.	1.5	42
30	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	7.0	40
31	High-resolution Whole-Genome Analysis of Skull Base Chordomas Implicates FHIT Loss in Chordoma Pathogenesis. <i>Neoplasia</i> , 2012, 14, 788-IN4.	5.3	37
32	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37
33	Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. <i>Journal of Neurosurgery</i> , 2014, 121, 1434-1445.	1.6	35
34	Notch1-Induced Brain Tumor Models the Sonic Hedgehog Subgroup of Human Medulloblastoma. <i>Cancer Research</i> , 2013, 73, 5381-5390.	0.9	29
35	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	7.7	28
36	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. <i>Oncotarget</i> , 2015, 6, 3359-3374.	1.8	23

#	ARTICLE	IF	CITATIONS
37	MyoD Is a Tumor Suppressor Gene in Medulloblastoma. <i>Cancer Research</i> , 2013, 73, 6828-6837.	0.9	21
38	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. <i>Nature Communications</i> , 2020, 11, 1825.	12.8	21
39	Epigenetic States of Cells of Origin and Tumor Evolution Drive Tumor-Initiating Cell Phenotype and Tumor Heterogeneity. <i>Cancer Research</i> , 2014, 74, 4864-4874.	0.9	20
40	Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 125-131.	1.2	20
41	HEGELIAN PHENOMENOLOGY AND ROBOTICS. <i>International Journal of Machine Consciousness</i> , 2011, 03, 219-235.	1.0	6
42	The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response. <i>Cancer Research and Cellular Therapeutics</i> , 2019, 3, .	0.0	3
43	Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors. <i>Cancer Cell</i> , 2010, 17, 413.	16.8	0
44	Abstract 3109: Myc confers aggressive medulloblastoma phenotypes by regulating cell migration and adhesion genes. , 2010, , .		0
45	Abstract 1445: Integrative genomics identifies actionable targets for therapy in medulloblastoma subgroups. , 2012, , .		0
46	Abstract 1428: A CpG island methylator phenotype defines a clinically aggressive subgroup of posterior fossa ependymoma. , 2012, , .		0
47	Abstract 3552: Subgroup-specific pattern of recurrence in medulloblastoma.. , 2013, , .		0
48	Response. <i>Journal of Neurosurgery</i> , 2014, 121, 1433.	1.6	0
49	CNGPLD: caseâ€“control copy-number analysis using Gaussian process latent difference. <i>Bioinformatics</i> , 2022, , .	4.1	0
50	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 337-354.	1.4	0